Fig. 8: An in vivo-compatible CeTEAM PARPi-nLuc biosensor for multiplexed tracking of drug binding in live animals.
From: Coupling cellular drug-target engagement to downstream pharmacology with CeTEAM
a Graphical overview of in vivo experiments with constitutive expression PARP1 L713F-nLuc/akaLuc subcutaneous HCT116 xenografts treated with either vehicle or 60 mg/kg niraparib. n = 7 total mice per group. b Representative bioluminescence (radiance) overlays of mice treated as in a following administration of fluorofurimazine (nLuc) or AkaLumine HCl (akaLuc). Radiance intensity in psuedocolor representation. c akaLuc-normalized quantification of in vivo L713F-nLuc signals following vehicle (gray) or niraparib (orange) treatment from two experimental arms. d Ex vivo L713F-nLuc (blue gradient; 1,149,410 to 17,154,040 RLU) and akaLuc (circle size; 137,106 to 401,261 RLU) luminescence intensity representations of each tumor. e Quantitation of ex vivo, akaLuc-normalized L713F-nLuc bioluminescence following vehicle (gray) or niraparib (orange) treatment. For c and e, means (nc=7; ne = 4) and 95% confidence intervals are shown, as well as P values from unpaired, two-tailed t tests (t, dfc = 4.969, 12; t, dfe = 4.871, 6).
